These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15538111)

  • 1. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
    Bhargava R; Lal P; Chen B
    Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
    Bánkfalvi A; Simon R; Brandt B; Bürger H; Vollmer I; Dockhorn-Dworniczak B; Lellé RJ; Boecker W
    Histopathology; 2000 Nov; 37(5):411-9. PubMed ID: 11119122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
    Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
    Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
    Selvarajan S; Tan SY; Sii LH; Tan PH
    Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization.
    Loring P; Cummins R; O'Grady A; Kay EW
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):194-200. PubMed ID: 15894935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.